为肝细胞癌武装 GPC3 CAR-T 细胞:多少才足够,下一步是什么?
Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Interleukin-21 receptor signaling promotes metabolic dysfunction-associated steatohepatitis-driven hepatocellular carcinoma by inducing immunosuppressive IgA(+) B cells.
Interleukin-21 receptor signaling promotes metabolic dysfunction-associated steatohepatitis-driven hepatocellular carcinoma by inducing immunosuppressive IgA(+) B cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
IL-21R 通过在 MASH 驱动的肝细胞癌发生中诱导 IgA + B 细胞发挥促癌作用。靶向 IL-21R 信号代表了一种潜在的治疗策略。
免疫监视失调与代谢功能障碍相关脂肪性肝炎(MASH)驱动的肝细胞癌(HCC)的发生密切相关;然而,其潜在机制仍不清楚。在此,我们旨在确定白细胞介素-21受体(IL-21R)在MASH驱动的HCC中的作用。
采用免疫组织化学染色评估IL-21R在人HCC标本中的临床意义。此外,在STAM模型中评估小鼠IL-21R的表达。此后,在IL-21R缺陷小鼠和野生型对照之间应用两种不同的MASH驱动HCC小鼠模型,以探索IL-21R在MASH驱动HCC中的作用。为进一步阐明IL-21R影响MASH驱动HCC的潜在机制,进行了全转录组测序、流式细胞术和过继性淋巴细胞转移。最后,进行流式细胞术、酶联免疫吸附试验、免疫荧光染色、染色质免疫沉淀试验和western blotting,以探索IL-21R诱导IgA + B细胞的机制。
高表达 IL-21R 的 HCC 患者表现出较差的无复发生存期、晚期 TNM 分期和严重脂肪变性。此外,IL-21R 被证明在小鼠肝脏肿瘤中上调。特别是,IL-21R 的缺失阻碍了 MASH 驱动的肝癌发生,并显著减少了脂质积累。此外,在缺乏 IL-21R 的情况下,由于免疫抑制性 IgA + B 细胞减少,细胞毒性 CD8 + T 淋巴细胞活化得到增强。在机制上,IL-21R-STAT1-c-Jun/c-Fos 调控轴在 MASH 驱动的 HCC 中被激活,从而促进 Igha 的转录,导致 IgA + B 细胞的诱导。
Dysregulation of immune surveillance is tightly linked to the development of metabolic dysfunction-associated steatohepatitis (MASH)-driven hepatocellular carcinoma (HCC); however, its underlying mechanisms remain unclear. Herein, we aimed to determine the role of interleukin-21 receptor (IL-21R) in MASH-driven HCC.
The clinical significance of IL-21R was assessed in human HCC specimens using immunohistochemistry staining. Furthermore, the expression of IL-21R in mice was assessed in the STAM model. Thereafter, two different MASH-driven HCC mouse models were applied between IL-21R-deficient mice and wild type controls to explore the role of IL-21R in MASH-driven HCC. To further elucidate the potential mechanisms by which IL-21R affected MASH-driven HCC, whole transcriptome sequencing, flow cytometry and adoptive lymphocyte transfer were performed. Finally, flow cytometry, enzyme-linked immunosorbent assay, immunofluorescent staining, chromatin immunoprecipitation assay and western blotting were conducted to explore the mechanism by which IL-21R induced IgA + B cells.
HCC patients with high IL-21R expression exhibited poor relapse-free survival, advanced TNM stage and severe steatosis. Additionally, IL-21R was demonstrated to be upregulated in mouse liver tumors. Particularly, ablation of IL-21R impeded MASH-driven hepatocarcinogenesis with dramatically reduction of lipid accumulation. Moreover, cytotoxic CD8 + T lymphocyte activation was enhanced in the absence of IL-21R due to the reduction of immunosuppressive IgA + B cells. Mechanistically, the IL-21R-STAT1-c-Jun/c-Fos regulatory axis was activated in MASH-driven HCC and thus promoted the transcription of Igha, resulting in the induction of IgA + B cells.
IL-21R plays a cancer-promoting role by inducing IgA + B cells in MASH-driven hepatocarcinogenesis. Targeting IL-21R signaling represents a potential therapeutic strategy for cancer therapy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。